Payment overview · 2025
General Payments
$14,484.01
56 reported records · 21 companies
Healthcare provider profile · identity verified
Julio Cesar Ortiz, DPM
Podiatric Medicine & Surgery Service Providers|Podiatrist|Foot Surgery · PALM BEACH GARDENS, FL · NPI 1154542512
Verified facts
What the public records show
CMS Open Payments records show Julio Cesar Ortiz, DPM received $14,484.01 in general payments during 2025 across 56 reported records.
Linvatec Corporation accounted for 68.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 39 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Linvatec Corporation | Unresolved — no canonical attribution shown | $9,842.15 | 68.0% | 11 | 2025 |
| Orthofix Medical, Inc. | Unresolved — no canonical attribution shown | $1,629.51 | 11.2% | 8 | 2025 |
| Paragon 28, Inc. | Unresolved — no canonical attribution shown | $1,045.07 | 7.2% | 4 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $252.93 | 1.8% | 6 | 2025 |
| TREACE MEDICAL CONCEPTS, INC. | Unresolved — no canonical attribution shown | $217.87 | 1.5% | 6 | 2025 |
| Acera Surgical, Inc. | Unresolved — no canonical attribution shown | $199.92 | 1.4% | 2 | 2025 |
| DJO, LLC | Unresolved — no canonical attribution shown | $172.66 | 1.2% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $153.85 | 1.1% | 2 | 2025 |
| Bone Support Inc. | Unresolved — no canonical attribution shown | $130.72 | 0.9% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $127.75 | 0.9% | 1 | 2025 |
| Integra LifeSciences Corporation | Unresolved — no canonical attribution shown | $125.82 | 0.9% | 2 | 2025 |
| Novastep Inc. | Unresolved — no canonical attribution shown | $112.66 | 0.8% | 1 | 2025 |
| Pacira Pharmaceuticals Incorporated | Unresolved — no canonical attribution shown | $109.14 | 0.8% | 1 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $82.32 | 0.6% | 2 | 2025 |
| Kerecis Limited | Unresolved — no canonical attribution shown | $56.20 | 0.4% | 1 | 2025 |
| Royal Biologics, Inc. | Unresolved — no canonical attribution shown | $50.50 | 0.3% | 1 | 2025 |
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $49.80 | 0.3% | 1 | 2025 |
| DePuy Synthes Sales Inc. | Unresolved — no canonical attribution shown | $44.69 | 0.3% | 1 | 2025 |
| TRICE MEDICAL, INC. | Unresolved — no canonical attribution shown | $41.68 | 0.3% | 1 | 2025 |
| Flower Orthopedics Coporation | Unresolved — no canonical attribution shown | $23.89 | 0.2% | 1 | 2025 |
| MIMEDX Group, Inc. | Unresolved — no canonical attribution shown | $14.88 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Travel and Lodging | $5,636.36 | 11 |
| Royalty or License | $4,188.77 | 4 |
| Food and Beverage | $2,658.88 | 40 |
| Consulting Fee | $2,000.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| COLINK 2 Normalized: colink 2 |
Device | Linvatec Corporation | $8,588.77 | 6 | 2025 |
Source payment records
|
|||||
| COLINK PLATING SYSTEM Normalized: colink plating system |
Device | Linvatec Corporation | $3,327.66 | 3 | 2025 |
Source payment records
|
|||||
| TrueLok Normalized: truelok |
Device | Orthofix Medical, Inc. | $1,629.51 | 8 | 2025 |
Source payment records
|
|||||
| COLINK MFX Normalized: colink mfx |
Device | Linvatec Corporation | $662.36 | 1 | 2025 |
Source payment records
|
|||||
| Monkey Rings Normalized: monkey rings |
Device | Paragon 28, Inc. | $554.11 | 3 | 2025 |
Source payment records
|
|||||
| Portfolio Normalized: portfolio |
Device | Paragon 28, Inc. | $490.96 | 1 | 2025 |
Source payment records
|
|||||
| BIOBRACE 23MM Normalized: biobrace 23mm |
Device | Linvatec Corporation | $319.24 | 3 | 2025 |
Source payment records
|
|||||
| COLINK NEOFUSE Normalized: colink neofuse |
Device | Linvatec Corporation | $271.78 | 1 | 2025 |
Source payment records
|
|||||
| Restrata Wound Matrix Normalized: restrata wound matrix |
Device | Acera Surgical, Inc. | $199.92 | 2 | 2025 |
Source payment records
|
|||||
| CMF Normalized: cmf |
Device | DJO, LLC | $172.66 | 2 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $153.85 | 2 | 2025 |
Source payment records
|
|||||
| 5MS Normalized: 5ms |
Device | Linvatec Corporation | $147.07 | 1 | 2025 |
Source payment records
|
|||||
| GRAFIX PL Normalized: grafix pl |
Biological | Smith+Nephew, Inc. | $135.36 | 1 | 2025 |
Source payment records
|
|||||
| STRAVIX Normalized: stravix |
Biological | Smith+Nephew, Inc. | $135.36 | 1 | 2025 |
Source payment records
|
|||||
| CERAMENT G Normalized: cerament g |
Device | Bone Support Inc. | $130.72 | 1 | 2025 |
Source payment records
|
|||||
| CERAMENTBONE VOID FILLER Normalized: ceramentbone void filler |
Device | Bone Support Inc. | $130.72 | 1 | 2025 |
Source payment records
|
|||||
| General - Vascular Intervention Normalized: general vascular intervention |
Device | Boston Scientific Corporation | $127.75 | 1 | 2025 |
Source payment records
|
|||||
| NEXIS Normalized: nexis |
Device | Novastep Inc. | $112.66 | 1 | 2025 |
Source payment records
|
|||||
| Exparel Normalized: exparel |
Drug | Pacira Pharmaceuticals Incorporated | $109.14 | 1 | 2025 |
Source payment records
|
|||||
| Integra Normalized: integra |
Device | Integra LifeSciences Corporation | $92.31 | 1 | 2025 |
Source payment records
|
|||||
| Integra Dermal Regeneration Template Normalized: integra dermal regeneration template |
Device | Integra LifeSciences Corporation | $92.31 | 1 | 2025 |
Source payment records
|
|||||
| PRIMATRIX Normalized: primatrix |
Device | Integra LifeSciences Corporation | $92.31 | 1 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $86.52 | 4 | 2025 |
Source payment records
|
|||||
| LAPIPLASTY SYSTEM 1 Normalized: lapiplasty system 1 |
Device | TREACE MEDICAL CONCEPTS, INC. | $71.99 | 1 | 2025 |
Source payment records
|
|||||
| TMC PSI CUT GUIDE SYSTEM Normalized: tmc psi cut guide system |
Device | TREACE MEDICAL CONCEPTS, INC. | $67.20 | 2 | 2025 |
Source payment records
|
|||||
| Kerecis GraftGuide Normalized: kerecis graftguide |
Device | Kerecis Limited | $56.20 | 1 | 2025 |
Source payment records
|
|||||
| Kerecis SurgiClose Normalized: kerecis surgiclose |
Device | Kerecis Limited | $56.20 | 1 | 2025 |
Source payment records
|
|||||
| PURAPLY WOUND MATRIX Normalized: puraply wound matrix |
Device | Organogenesis Inc. | $49.80 | 1 | 2025 |
Source payment records
|
|||||
| MOTOBAND Normalized: motoband |
Device | DePuy Synthes Sales Inc. | $44.69 | 1 | 2025 |
Source payment records
|
|||||
| N/A Normalized: n a |
Device | Stryker Corporation | $43.84 | 1 | 2025 |
Source payment records
|
|||||
| ALLOMATRIX Normalized: allomatrix |
Device | Stryker Corporation | $38.48 | 1 | 2025 |
Source payment records
|
|||||
| AUGMENT INJECTABLE Normalized: augment injectable |
Device | Stryker Corporation | $38.48 | 1 | 2025 |
Source payment records
|
|||||
| BIODFACTOR Normalized: biodfactor |
Device | Integra LifeSciences Corporation | $33.51 | 1 | 2025 |
Source payment records
|
|||||
| BIODOPTIX Normalized: biodoptix |
Device | Integra LifeSciences Corporation | $33.51 | 1 | 2025 |
Source payment records
|
|||||
| BIODRESTORE Normalized: biodrestore |
Device | Integra LifeSciences Corporation | $33.51 | 1 | 2025 |
Source payment records
|
|||||
| BIOFIX Normalized: biofix |
Device | Integra LifeSciences Corporation | $33.51 | 1 | 2025 |
Source payment records
|
|||||
| MEDIHONEY Normalized: medihoney |
Device | Integra LifeSciences Corporation | $33.51 | 1 | 2025 |
Source payment records
|
|||||
| Pico 14 Normalized: pico 14 |
Device | Smith+Nephew, Inc. | $31.05 | 1 | 2025 |
Source payment records
|
|||||
| TMC NANOPLASTY SYSTEM Normalized: tmc nanoplasty system |
Device | TREACE MEDICAL CONCEPTS, INC. | $27.16 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Ciclopirox | Ciclopirox | 297 | 147 |
| Ammonium Lactate | Ammonium Lactate | 111 | 54 |
| Meloxicam | Meloxicam | 101 | 68 |
| Gentamicin Sulfate | Gentamicin Sulfate | 89 | 50 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 74 | 37 |
| Cephalexin | Cephalexin | 32 | 29 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Methylprednisolone | Methylprednisolone | 20 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 20 | 20 |
| Gabapentin | Gabapentin | 17 | suppressed |
| Clotrimazole | Clotrimazole | 16 | suppressed |
| Xarelto | Rivaroxaban | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $14,484.01 · 56 records | Linvatec Corporation | 5MS, ALLOMATRIX, AUGMENT INJECTABLE, BIOBRACE 23MM, BIODFACTOR, BIODOPTIX, BIODRESTORE, BIOFIX, CERAMENT G, CERAMENTBONE VOID FILLER, CMF, COLINK 2, COLINK MFX, COLINK NEOFUSE, COLINK PLATING SYSTEM, COLLAGENASE SANTYL, Exparel, GRAFIX PL, General - Vascular Intervention, Integra, Integra Dermal Regeneration Template, KRYSTEXXA, Kerecis GraftGuide, Kerecis SurgiClose, LAPIPLASTY SYSTEM 1, MEDIHONEY, MOTOBAND, Monkey Rings, N/A, NEXIS, PRIMATRIX, PURAPLY WOUND MATRIX, Pico 14, Portfolio, Restrata Wound Matrix, STRAVIX, TMC NANOPLASTY SYSTEM, TMC PSI CUT GUIDE SYSTEM, TrueLok | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error